About Onconic Therapeutics
Onconic Therapeutics is a company based in Seoul (South Korea) founded in 2020. Onconic Therapeutics has raised $19.9 million across 1 funding round from investors including Aju IB Investment, Stonebridge Capital and Premier Partners. The company has 29 employees as of December 31, 2024. Onconic Therapeutics operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, Tonix Pharma, PanTher Therapeutics and RedHill Biopharma, among others.
- Headquarter Seoul, South Korea
- Employees 29 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Onconic Therapeutics, Inc.
-
Annual Revenue
$10.06 M (USD)-29.53as on Dec 31, 2024
-
Net Profit
-$5.49 M (USD)-581as on Dec 31, 2024
-
EBITDA
-$2.95 M (USD)-261.46as on Dec 31, 2024
-
Total Equity Funding
$19.9 M (USD)
in 1 rounds
-
Latest Funding Round
$19.9 M (USD), Series B
Dec 09, 2022
-
Investors
Aju IB Investment
& 8 more
-
Employee Count
29
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Onconic Therapeutics
Onconic Therapeutics is a publicly listed company on the KRX with ticker symbol 476060 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Onconic Therapeutics
Onconic Therapeutics has successfully raised a total of $19.9M through 1 strategic funding round. The most recent funding activity was a Series B round of $19.9 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Onconic Therapeutics
Onconic Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Aju IB Investment, Stonebridge Capital and Premier Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech and life sciences focused VC & PE firm
|
Locked | Locked | Locked | |
|
Private equity & venture capital firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Onconic Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Onconic Therapeutics
Investment portfolio details for Onconic Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Onconic Therapeutics
Detailed financials for Onconic Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Onconic Therapeutics Comparisons
Peer comparison for Onconic Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Onconic Therapeutics
Onconic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, Tonix Pharma, PanTher Therapeutics and RedHill Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal diseases are developed and provided.
|
Detailed competitors of Onconic Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Onconic Therapeutics
Complete news archive for Onconic Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Onconic Therapeutics
Onconic Therapeutics was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Onconic Therapeutics is headquartered in Seoul, South Korea.
John Kim is the current CEO of Onconic Therapeutics.
Onconic Therapeutics is a funded company, having raised a total of $19.9M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Onconic Therapeutics is 29.
Annual revenue of Onconic Therapeutics is $10.06M as on Dec 31, 2024.
Onconic Therapeutics was founded in 2020 and is headquartered in Seoul, South Korea. Focus is placed on developing pharmaceutical treatments within the oncology and gastroenterology sectors. The lead candidate, JPI-547, functions as a dual inhibitor targeting PARP and Tankyrase for pancreatic cancer applications. Another program involves JP-1366, a proton pump inhibitor designed for reflux esophagitis management. Operations emphasize drug candidate advancement through research and clinical stages.
Onconic Therapeutics's top competitors include Ironwood Pharma, PanTher Therapeutics and Tonix Pharma.
Yes, Onconic Therapeutics is publicly traded on KRX under the ticker symbol 476060.
Onconic Therapeutics has 9 investors. Key investors include Aju IB Investment, Stonebridge Capital, Premier Partners, BNH INVESTMENT, and DAOL Ventures.
The ticker symbol of Onconic Therapeutics is 476060 on KRX.